SEPTInvestingStart Free

MRNA 8-K: Executive departure

Filed with the SEC on · accession 0001682852-26-000205

MRNA filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -3.4% by the first close after the filing.

Summary of the filing

Moderna's Chief Legal Officer Shannon Thyme Klinger will retire effective March 31, 2027, under a Transitional Services and Retirement Agreement providing severance of $1,628,300 plus potential litigation-contingent payments of up to $8,000,000.

For details, click here →How to read a 8-K →

Key details

Severance payments over twelve months following Retirement Date$1.6M
Contingent payment if Company prevails in Arbutus/Genevent litigation$2.5M
Contingent payment subject to result of Pfizer/BioNTech litigation$5.5M
RegistrantModerna, Inc.
Litigation counterpartyArbutus Biopharma Corporation
Litigation counterpartyGenevent Sciences, GmbH
Litigation counterpartyPfizer, Inc.
Litigation counterpartyBioNTech SE
Chief legal officerShannon Thyme Klinger
Chief financial officerJames M. Mock

How MRNA stock reacted

Close before

$231.35

Nov 12, 2026

First close after

-3.45%

$223.37

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for MRNA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MRNA?

Click here

Frequently asked questions

What did MRNA file with the SEC on Nov 13, 2026?

MRNA filed a 8-K (Executive departure). Moderna's Chief Legal Officer Shannon Thyme Klinger will retire effective March 31, 2027, under a Transitional Services and Retirement Agreement providing severance of $1,628,300 plus potential litigation-contingent payments of up to $8,000,000.

What does a executive departure mean for MRNA stock?

Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did MRNA stock react to this filing?

MRNA closed at $231.35 before the filing and $223.37 on Nov 13, 2026 (-3.45%).

Other MRNA SEC filings

Get alerts when MRNA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
MRNA overviewMRNA analysisMRNA newsLatest SEC filings